Sheridan William P 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Jun 1, 2021
Insider Transaction Report
Form 4
Sheridan William P
SR VP - CMO
Transactions
- Exercise/Conversion
Common Stock
2021-05-27$5.59/sh+35,701$199,569→ 75,135 total - Sale
Common Stock
2021-05-28$15.02/sh−91,814$1,379,046→ 14,475 total - Exercise/Conversion
Common Stock
2021-05-27$4.73/sh+24,959$118,056→ 39,434 total - Sale
Common Stock
2021-05-27$15.00/sh−71,759$1,076,385→ 14,475 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-28−21,614→ 0 totalExercise: $4.73From: 2013-03-01Exp: 2022-03-01→ Common Stock (21,614 underlying) - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-27−35,701→ 64,299 totalExercise: $5.59From: 2015-03-09Exp: 2022-03-09→ Common Stock (35,701 underlying) - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-28−5,901→ 0 totalExercise: $5.45From: 2015-05-13Exp: 2023-08-08→ Common Stock (5,901 underlying) - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-28−64,299→ 0 totalExercise: $5.59From: 2015-03-09Exp: 2022-03-09→ Common Stock (64,299 underlying) - Exercise/Conversion
Common Stock
2021-05-28$5.59/sh+64,299$359,431→ 100,388 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-27−11,099→ 5,901 totalExercise: $5.45From: 2015-05-13Exp: 2023-08-08→ Common Stock (11,099 underlying) - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-27−24,959→ 21,614 totalExercise: $4.73From: 2013-03-01Exp: 2022-03-01→ Common Stock (24,959 underlying) - Exercise/Conversion
Common Stock
2021-05-27$5.45/sh+11,099$60,490→ 86,234 total - Exercise/Conversion
Common Stock
2021-05-28$4.73/sh+21,614$102,234→ 36,089 total - Exercise/Conversion
Common Stock
2021-05-28$5.45/sh+5,901$32,160→ 106,289 total
Footnotes (3)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.
- [F2]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.